There is still no cure for Huntington’s disease (HD), but neurologists are improving patients’ lives in concrete ways: earlier and more careful genetic diagnosis, FDA-approved medicines that reduce chorea (involuntary movements), coordinated team care that addresses mood, thinking, swallowing, and mobility, and access to clinical trials of therapies designed to slow the disease itself. This article explains what HD is, how neurologists diagnose and manage it today, what research is showing as of 2026, and where families can find support.
What is Huntington’s disease?
Huntington’s disease is an inherited brain disorder that causes nerve cells in parts of the brain, especially the striatum, to gradually break down. It affects three areas of life: movement, thinking (cognition), and emotions and behavior.
HD is caused by an expanded stretch of repeated DNA letters (the “CAG repeat”) in the HTT gene. It is inherited in an autosomal dominant pattern, which means each child of a parent with the gene expansion has a 50 percent chance of inheriting it. People with 40 or more CAG repeats will develop the disease if they live a normal lifespan, while 36 to 39 repeats carry a risk of developing it with reduced likelihood.
Symptoms most often begin between ages 30 and 50, though they can start at any age. When symptoms begin before age 20, it is called juvenile Huntington’s disease, which often looks different (more stiffness and seizures, less chorea). After symptoms start, the disease typically progresses over about 10 to 25 years.
Common symptoms
| Area | Typical symptoms |
|---|---|
| Movement | Chorea (jerky, dance-like movements), clumsiness, balance problems, slurred speech, difficulty swallowing, later stiffness |
| Thinking | Trouble planning and organizing, slowed thinking, difficulty switching tasks, poor awareness of one’s own symptoms |
| Mood and behavior | Depression, irritability, anxiety, apathy, obsessive thinking; increased risk of suicide |
Changes in mood and thinking often appear years before obvious movement symptoms, and families frequently say these are harder to live with than chorea.
How neurologists diagnose Huntington’s disease
Neurologists, especially movement disorder specialists, diagnose HD by combining a detailed neurological exam, a family history, and a blood test that counts CAG repeats in the HTT gene. Brain imaging may be used to rule out other causes but cannot confirm HD on its own.
Diagnostic vs. predictive testing
There is an important difference between testing someone who already has symptoms (diagnostic testing) and testing someone at risk who feels well (predictive testing). Because a positive predictive result has life-changing implications and there is no cure, established guidelines recommend that predictive testing happen through a structured process with genetic counseling before and after results, and often a psychological assessment. Many at-risk people choose not to test, and that is a valid decision.
Couples who carry the gene expansion and are planning a family can discuss options such as preimplantation genetic testing with IVF with a genetic counselor.
Treating symptoms: what neurologists can do today
Medicines for chorea
The FDA has approved three drugs for chorea in Huntington’s disease, all of which work by reducing dopamine signaling (they are VMAT2 inhibitors):
- Tetrabenazine (Xenazine), approved in 2008.
- Deutetrabenazine (Austedo), approved for HD chorea in 2017.
- Valbenazine (Ingrezza), approved for HD chorea in 2023.
These medicines can reduce involuntary movements, but they carry a boxed warning about depression and suicidal thoughts in people with HD, so neurologists monitor mood closely. Some antipsychotic medicines are also used off label, particularly when chorea occurs alongside irritability or psychosis. Not everyone with chorea needs treatment: if movements are mild and not bothering the person, a neurologist may hold off.
Treating mood and behavior
Depression, anxiety, and irritability are common and treatable. Neurologists often work with psychiatrists to use antidepressants, mood stabilizers, or antipsychotics as needed, along with counseling. Screening for suicide risk is a routine and important part of HD care.
The multidisciplinary care team
Perhaps the biggest improvement in HD care has been the shift to team-based care, often coordinated by a neurologist. A typical team may include:
- Physical therapists to work on balance, strength, and fall prevention.
- Occupational therapists to adapt the home and daily tasks so people stay independent longer.
- Speech-language pathologists to help with communication and to assess swallowing, since swallowing problems raise the risk of choking and pneumonia.
- Dietitians, because many people with HD lose weight and may need significantly more calories.
- Psychiatrists, psychologists, and social workers for mental health, family support, and planning around work, driving, and finances.
- Genetic counselors for the patient and at-risk relatives.
Managing pain and physical strain
Pain in HD is easy to overlook. Falls, constant movement, posture changes, and muscle stiffness can cause musculoskeletal pain, and people with HD may have difficulty describing what they feel. Neurologists increasingly ask about pain directly and may involve pain management specialists. As with any chronic pain condition, from HD-related strain to general sugar land back pain care, the best results come from a tailored plan that combines physical therapy, careful medication choices, and attention to the underlying cause rather than one-size-fits-all treatment.
Lifestyle and everyday strategies
No diet or exercise program has been proven to slow HD, but neurologists commonly encourage habits that support function and well-being:
- Regular physical activity, adapted for safety, to maintain strength, balance, and mood.
- Calorie-dense, easy-to-swallow meals when weight loss or swallowing difficulty appears.
- Predictable daily routines, written schedules, and breaking tasks into steps to offset planning difficulties.
- Staying socially connected, which helps with mood and reduces isolation.
- Early legal and financial planning, including advance directives, while the person can fully take part in decisions.
Research: therapies aimed at slowing the disease
Current approved treatments manage symptoms only. Much of today’s research instead targets the cause: lowering the amount of the harmful huntingtin protein. Approaches include gene therapies delivered directly into the brain, antisense oligonucleotides (ASOs), and oral drugs that change how the HTT gene’s instructions are processed.
The most closely watched candidate is AMT-130, an investigational one-time gene therapy from uniQure that is delivered by brain surgery. In 2025, the company reported three-year results from a small early-stage study suggesting slower progression at the higher dose compared with an external comparison group. As of mid-2026, uniQure said it had agreed with the FDA that seeking accelerated approval based on existing data was reasonable, while discussions on a confirmatory study continued. It has not been approved, and results from small studies need confirmation. Other programs, including Roche’s tominersen ASO and PTC Therapeutics’ oral drug votoplam, remain in clinical trials.
Large observational studies such as Enroll-HD, which follows thousands of HD families worldwide, help researchers understand how the disease progresses and design better trials. Neurologists at specialized centers can tell patients which trials they may qualify for, and ClinicalTrials.gov lists current studies.
Traditional vs. modern approaches to HD care
| Aspect | Older approach | Current approach |
|---|---|---|
| Diagnosis | Based on symptoms, often late | Genetic confirmation, with counseling-based predictive testing for at-risk relatives |
| Treatment | Few options, mostly sedating drugs | FDA-approved chorea drugs plus targeted mood and cognitive care |
| Care model | Single doctor | Multidisciplinary team, often at a specialized center |
| Research | Limited | Trials of huntingtin-lowering therapies and long-term observational studies |
Support and resources for families
The Huntington’s Disease Society of America (HDSA) supports a national network of HDSA Centers of Excellence, which offer multidisciplinary care, along with social workers, support groups, and educational materials. The National Institute of Neurological Disorders and Stroke (NINDS) publishes plain-language information on HD and research. Caregivers, who often provide years of support, benefit from respite care and their own counseling. For family members caring for older relatives, our overview of geriatrics may also be useful background.
Frequently asked questions
Is there a cure for Huntington’s disease?
No. Current treatments manage symptoms. Several therapies designed to slow the disease are in clinical trials or regulatory review, but none has been approved yet.
How is Huntington’s disease inherited?
It is autosomal dominant. Each child of a parent with the HTT gene expansion has a 50 percent chance of inheriting it, regardless of sex.
What medicines treat Huntington’s chorea?
The FDA has approved tetrabenazine, deutetrabenazine, and valbenazine for chorea in HD. Doctors monitor mood closely because these drugs carry warnings about depression and suicidal thoughts.
What kind of doctor treats Huntington’s disease?
A neurologist, ideally a movement disorder specialist, usually leads care, working with psychiatrists, therapists, dietitians, social workers, and genetic counselors.
Should I get tested if HD runs in my family?
It is a personal decision. Guidelines recommend genetic counseling before and after predictive testing so you can weigh the emotional, practical, and insurance implications.
This article is general information, not medical advice. Talk to a neurologist or genetic counselor about your own situation.
